South Korean health-tech company Neurophet is using one of the biotech industry's biggest annual gatherings — BIO USA — to put its artificial intelligence tools for brain imaging in front of potential partners around the world, according to PR Newswire.
The company is showcasing what it calls its "Brain Imaging AI Solutions" at the conference, with the explicit goal of accelerating business development collaborations on a global scale. BIO USA draws thousands of pharmaceutical executives, investors, and research organizations each year, making it a high-profile venue for companies seeking licensing deals, co-development agreements, or distribution partnerships.
Neurophet's technology sits at the intersection of two fast-moving fields: medical imaging and AI-assisted diagnostics. Brain imaging analysis is a particularly demanding application — the human brain is extraordinarily complex, and subtle changes in structure or activity can signal conditions ranging from Alzheimer's disease to multiple sclerosis. AI tools that can process and interpret these scans quickly and consistently have attracted significant interest from drug developers who need reliable biomarkers to measure whether a treatment is working.
By attending BIO USA, Neurophet is signaling that it sees its next stage of growth coming from outside its home market, likely through partnerships with larger pharmaceutical companies or research institutions that already have global reach.
If Neurophet's AI tools gain traction through deals brokered at events like this, it could accelerate the use of automated brain imaging analysis in clinical trials and, eventually, routine patient care.